New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

The American Heart Association 2022 Scientific Sessions included 35 late-breaking studies and 39 featured science sessions presented at the meeting in Chicago, Nov. 5-7. Here is the list of all these studies with links to more information on the data.

Dozens of medical societies have signed a new letter urging Congress to stop upcoming Medicare payment cuts. “The Medicare payment system remains on an unsustainable path threatening beneficiaries’ access to physicians," they wrote. 

Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

Researchers examined data from nearly 5,400 patients, tracking such outcomes as myocardial infarction, stroke and all-cause mortality. 

Rising labor costs and high inflation rates are expected to drive up the annual U.S. national health expenditure by $370 billion by 2027, according to a recent report from McKinsey.

Experts found that compared to the average effective doses of organs, breast doses were higher, representing increased risks of breast cancer for women. 

The American Hospital Association (AHA) and the American Medical Association (AMA) have dropped their legal challenge to the interim final rule independent dispute resolution process of the No Surprises Act.